Company intelligence / Profile preview

Navignostics

Horgen, Zurich, Switzerlandnavignostics.com ↗

Ownership: Private
Employees: ~8
Development stage: Commercial

Overview

Navignostics has developed a proprietary spatial single-cell proteomics platform that enables detailed mapping of tumor protein expression at the cellular level. This approach supports personalized oncology by helping clinicians select optimal therapies based on individual tumor profiles. The company’s technology has been validated through translational research studies and is being developed into clinical diagnostic services. No clinical trial results are available yet as their main offering focuses on diagnostics rather than therapeutics.

Therapeutic areas: Oncology
Modalities: Spatial single-cell proteomicsAntibody-based detection
Industry: Protein Biomarker Diagnostics

Partnerships

Standard BioToolsMultiple undisclosed clinical and biotech partners

Beyond the preview

Go deeper on Navignostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Navignostics.

Explore the full profile